National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Berotralstat (Orladeyo®). HTA ID: 22031

Berotralstat is indicated for the routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/05/2022
Rapid review completed 03/06/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of berotralstat compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.